United States - English - NLM (National Library of Medicine)

tya pharmaceuticals - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - atomoxetine 25 mg - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) . [see clinical studies ( )] 14 a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of

United States - English - NLM (National Library of Medicine)

carilion materials management - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - atomoxetine 10 mg - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) . [see clinical studies ( )] 14 a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of

United States - English - NLM (National Library of Medicine)

carilion materials management - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) . [see clinical studies ( )] 14 a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of

United States - English - NLM (National Library of Medicine)

carilion materials management - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) . [see clinical studies ( )] 14 a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of

United States - English - NLM (National Library of Medicine)

carilion materials management - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) . [see clinical studies ( )] 14 a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - atomoxetine hydrochloride (unii: 57wvb6i2w0) (atomoxetine - unii:asw034s0b8) - atomoxetine hydrochloride 25 mg - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd). the efficacy of strattera capsules was established in seven clinical trials in outpatients with adhd: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15) [see clinical studies (14)]. a diagnosis of adhd (dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that cause impairment and that were present before age 7 years. the symptoms must be persistent, must be more severe than is typically observed in individuals at a comparable level of development, must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and must be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. the specific etiology of adhd is unknown, and there is no single diagnostic test. adequate

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 114.3mg equivalent to 100 mg atomoxetine free base - capsule - 100 mg - active: atomoxetine hydrochloride 114.3mg equivalent to 100 mg atomoxetine free base excipient: dimeticone gelatin   iron oxide red   iron oxide yellow   pregelatinised maize starch sodium laurilsulfate   tekprint black sw-9008   tekprint black sw-9010   titanium dioxide   - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 11.43mg equivalent to 10 mg atomoxetine free base - capsule - 10 mg - active: atomoxetine hydrochloride 11.43mg equivalent to 10 mg atomoxetine free base excipient: dimeticone gelatin pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9010 titanium dioxide - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 20.57mg equivalent to 18 mg atomoxetine free base - capsule - 18 mg - active: atomoxetine hydrochloride 20.57mg equivalent to 18 mg atomoxetine free base excipient: dimeticone gelatin iron oxide yellow pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9010 titanium dioxide - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - atomoxetine hydrochloride 28.57mg equivalent to 25 mg atomoxetine free base - capsule - 25 mg - active: atomoxetine hydrochloride 28.57mg equivalent to 25 mg atomoxetine free base excipient: dimeticone gelatin indigo carmine pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9010 titanium dioxide - strattera is indicated for the treatment of attention-deficit/hyperactivity disorder (adhd) as defined by dsm-iv criteria in children 6 years of age and older and adolescents.